






# Innovative pipeline





# Early pipeline

**30**

validated targets

---

**15**

programs in LO

---

**7**

preclinical candidate programs

---

- `4471 – inflammation
- `4399 – inflammation
- `4259 – inflammation
- `4124 – fibrosis
- `4059 – metabolic
- `4586 – fibrosis
- `4605 – fibrosis

**4**

Ph1 programs


---

- `3970 – inflammation
- `3667 – inflammation
- `555 – inflammation
- `2737 – kidney disease



# Filgotinib


potential for 5 launches in next 4 years



RA: rheumatoid arthritis; CD: Crohn's disease; UC: ulcerative colitis; AS: ankylosing spondylitis; PsA: psoriatic arthritis



# IPF & fibrosis portfolio





# Toledo: robust activity in *in vivo* models

		IBD	RA	Pso	PsA	SLE	OP	Fib
PanTOL	'3312	●	●	●	●	●	●	●
TOL2/3	'3970	●	●	●	●	●	●	●
TOL3	'4399	●	●	●	●	2020		
TOL2/3	'4605	2020						
TOLi	LO	2020						

green: preclinical activity; orange: insufficient preclinical activity  
Note: '3312 no longer actively developed



# Galápagos

**Pioneering** for patients

---

**We discover We dare We care**